EU and US could reach trade deal this weekend - Reuters
On Tuesday, BMO Capital analysts highlighted potential risks for Merck (NYSE:MRK) and Pfizer/BioNTech (NYSE:PFE/BNTX) stocks following RFK Jr.’s decision to remove 17 members of the Advisory Committee on Immunization Practices (ACIP). The move, detailed in a Wall Street Journal op-ed, aims to reshape the committee and restore public trust in vaccines. Pfizer , with its substantial $137.36 billion market capitalization and historically low price volatility (Beta: 0.49), remains a dominant player in the pharmaceutical sector.
The analysts noted that while this development introduces some uncertainty, it is seen more as a headline risk than a fundamental change in the sector. They mentioned that RFK Jr.’s previous appointments to health agencies did not result in drastic changes, suggesting that the current situation might follow a similar path. The after-hours share reactions were muted, indicating a limited immediate impact on the stocks. InvestingPro data shows Pfizer maintains strong financial health with a "GOOD" overall rating, suggesting resilience to market uncertainties.
The ACIP plays a crucial role in reviewing vaccine data, developing recommendations, and setting immunization schedules in the U.S. The full removal of its members allows the Trump administration to appoint new members sooner than expected, potentially leading to more critical evaluations of future vaccine recommendations.
Despite the potential negative implications for vaccine manufacturers, the analysts expect the impact on share prices to be muted. Previous concerns about new health agency appointees have not resulted in significant negative outcomes for the sector, which might temper the downside for Merck, Pfizer, and BioNTech (NASDAQ:BNTX) stocks.
Overall, the analysts suggest that while the changes to the ACIP could present challenges, the market has already priced in some of these risks, and the immediate effects on the stocks may be limited. According to InvestingPro, Pfizer currently appears undervalued and offers an attractive 7.18% dividend yield. Discover more insights and 8 additional ProTips about Pfizer’s investment potential with a subscription to InvestingPro’s comprehensive research platform.
In other recent news, Pfizer Inc. (NYSE:PFE) has been involved in several notable developments. Pfizer, in collaboration with Arvinas, submitted a New Drug Application to the U.S. Food and Drug Administration for vepdegestrant, a potential treatment for advanced breast cancer. This submission is based on promising Phase 3 trial results, and the drug has been granted fast track designation by the FDA. Additionally, Jefferies analysts have maintained a Buy rating on Pfizer, with a price target of $33, following the presentation of Phase 1 data on Pfizer’s sigvotatug vedotin in combination with pembrolizumab for lung cancer treatment.
Cantor Fitzgerald has kept its Neutral rating for Pfizer, with a price target of $24, amid ongoing changes in COVID-19 vaccine guidelines by health authorities. These changes could impact the use of Pfizer’s Comirnaty vaccine, a significant revenue source for the company. In another development, Pfizer has been in discussions with the Trump administration regarding drug pricing policies, although no commitments have been made. The discussions are part of efforts to implement a policy aimed at reducing prescription drug costs in the U.S.
Lastly, Pfizer, along with Moderna (NASDAQ:MRNA) and BioNTech, experienced a decline in stock value following the announcement of an overhaul of the Advisory Committee for Immunization Practices. This committee is responsible for evaluating vaccines and has faced scrutiny over transparency issues. The reconstitution aims to restore public trust in vaccine recommendations, which could affect future vaccine approvals and sales for these companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.